Laminin-derived peptides have been incorporated into the delivery systems of anti-tumor agents to enhance their specificity to highly expressed laminin receptors on cancer cells, including YIGSR for the 32/67 kD receptor, IKVAV for the α3β1 and α6β1 integrin receptors, AG73 for syndecan-2 receptor and C16Y for the αvβ3 integrin receptors (Dubey et al., 2010; Negishi et al., 2011; Hamano et al., 2012; Okur et al., 2016; Negishi and Nomizu, 2019). This evidence concerns the gene LAMB2 and cancer.